Treatment of TRAPS typically involves anti-inflammatory agents such as IL-1 inhibitors, with our patient experiencing clinical improvement on anakinra and canakinumab. This evidence concerns the gene IL1B and TNF receptor 1-associated periodic fever syndrome.